← Back to patent-cliff list
苯甲酸阿格列汀/盐酸吡格列酮
Tier C — Watch / tradeAlogliptin Benzoate/Pioglitazone Hydrochloride
武田药品工业株式会社
Originator
2011
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：DPP4、PPARγ
Brand：Oseni、Nesinaact、Liovel、Incresync
Indications (approved)：二型糖尿病
Regional status
US
批准上市
2013-01-25
EU
批准上市
2013-09-19
China
-
Japan
批准上市
2011-07-01
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Alogliptin Benzoate/Pioglitazone Hydrochloride?
Approved indications include: 二型糖尿病.
When does the Alogliptin Benzoate/Pioglitazone Hydrochloride patent expire?
No public expiry year is available for Alogliptin Benzoate/Pioglitazone Hydrochloride yet; this page updates once verified.
How do I get a quote for Alogliptin Benzoate/Pioglitazone Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24